Compare Amgen, Inc. (AMGN) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Texas Instruments Incorporated — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Texas Instruments Incorporated trades at $306.78 (market cap $283.46B). The key difference: Texas Instruments Incorporated is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | TXN | |
|---|---|---|
Market Cap | $196.12B | $283.46B |
Sector | Health | Technology |
52-Week High | $388.16 | $332.35 |
52-Week Low | $271.18 | $153.33 |
Enterprise Value | $241.41B | $292.40B |
Dividend Yield | 2.77% | 1.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Texas Instruments (TXN) trades at $311.51, up 0.94% today, showing strong technical momentum with a bullish moving average signal. The company reported mixed Q1 2026 earnings, beating expectations with $1.68 EPS versus $1.36 expected, while Q3 and Q4 2025 missed. Recent CFO transition to Julie Knecht signals stable leadership. Revenue grew to $17.68B in 2025 from $15.6B in 2024, with net income margin at 29.11%.
Outlook remains positive with 65 analysts showing 48% buy rating and $310.95 consensus target. Key risks include high valuation multiples (P/E 53.24) and rising debt-to-asset ratio (40.61% in 2025). AI-driven data center demand presents growth opportunity, but competition and macroeconomic pressures warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
